Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduced Intensity Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Sirolimus/Mycophenolate Mofetil/RGI-2001 Based GVHD Prevention: a Pilot Study

NCT04473911 is registered in ClinicalTrials.gov with Zachariah Michael DeFilipp as lead sponsor.

NCT NCT04473911
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04473911 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduced Intensity Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Sirolimus/Mycophenolate Mofetil/RGI-2001 Based GVHD Prevention: a Pilot Study
Lead sponsor
Zachariah Michael DeFilipp
Phase
Phase 1
Overall status
Completed
Start date
August 14, 2020
Completion date
August 19, 2024
Enrollment
25 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, acute myeloid leukemia, all, aml, blood stem cell transplant failure, chemosensitive hodgkin lymphoma, chronic myelomonocytic leukemia, cmml, graft vs host disease, gvhd, hodgkin lymphoma, mds, mpn, myelodysplastic syndromes, myeloproliferative disorder, non hodgkin lymphoma